Treating newly diagnosed central malignant germ cell tumors with teniposide and cisplatin
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two chemotherapy drugs—teniposide and cisplatin—for people who have just been diagnosed with a malignant germ cell tumor in the brain. The goal is to see if this treatment is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a newly diagnosed malignant germ cell tumor in the brain.
- You must have at least one tumor that can be measured on an MRI scan.
- Your overall health must be good enough to survive at least 6 months.
- Your blood cell counts and liver/kidney function must be within certain limits.
- You cannot be pregnant or breastfeeding, and you must use contraception if needed.
- You must not have had any prior cancer treatments or other serious medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how to manage germ cell tumors in children and young adults using careful monitoring for some patients and chemotherapy for others. It aims to see whether these approaches can control the cancer while avoiding unnecessary treatment when possible.
This trial tests a maintenance therapy combining zanzalintinib and etoposide after you've completed high-dose chemotherapy and a stem cell transplant for germ cell cancer. The goal is to see if this drug combination helps prevent the cancer from coming back.
This Phase 3 trial compares a faster chemotherapy approach versus the standard schedule for people with intermediate- or poor-risk metastatic germ cell tumors. The goal is to see which schedule works better and is safer enough to use as initial treatment.
This trial tests a second-line high-dose chemotherapy for germ cell tumors that have come back after initial treatment. It may be an option for patients whose cancer progressed after 3–4 cycles of standard platinum-based chemo.
This phase 2 study looks at whether taking oral etoposide after high-dose chemotherapy helps people with a certain type of testicular or ovarian cancer avoid relapse. If you qualify, you may be assigned to take the medicine or simply be monitored without additional treatment.
This study tests whether a combination of three drugs—teniposide, cisplatin, and serplulimab—can effectively treat extensive-stage small cell lung cancer (a fast-growing type of lung cancer that has spread). Serplulimab is an immunotherapy drug designed to help your immune system fight cancer.
Hear when a new Germ Cell Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.